Advances of Lefamulin: a new pleuromutilin antibiotic
10.16438/j.0513-4870.2020-1617
- VernacularTitle:人用截短侧耳素类新药Lefamulin的研究进展
- Author:
Xue-yao LI
1
;
Ji-shun LI
1
,
2
;
Zi-hao ZHU
1
;
Tao-ting-yue LI
3
;
Wen-xuan ZHANG
1
;
Jie XIA
1
;
Tian-lei LI
1
;
Song WU
1
Author Information
1. State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medical, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China
2. Guizhou University of Traditional Chinese Medicine, Guiyang 550001, China
3. Beijing No.161 High School, Beijing 100020, China
- Publication Type:Research Article
- Keywords:
pleuromutilin;
Lefamulin;
antibacterial activity;
community-acquired bacterial pneumonia
- From:
Acta Pharmaceutica Sinica
2021;56(4):1006-1015
- CountryChina
- Language:Chinese
-
Abstract:
Lefamulin (BC-3781) is a semi-synthetic pleuromutilin antibiotic, approved for the treatment of community-acquired bacterial pneumonia (CABP) by Food and Drug Administration (USA) in August 2019, with the commodity name of Xenleta. It is the first pleuromutilin antibiotics used for systemic treatment of bacterial infections in human. Lefamulin binds to the peptidyl transferase center of the 50S ribosomal subunit to prevent peptide transfer, thus inhibits protein synthesis. Lefamulin displays expanded activity against gram-positive organisms, and also shows high activity against atypical microorganism like Mycoplasma pneumoniae. This review discusses the mechanism, bacterial spectrum of activity, preclinical and clinical data of Lefamulin.
